COPD

Pulmonary conditions like asthma could often lead to the development of chronic cough.

New data shows nearly 40% of chronic lung disease patients from a Portuguese hospital died within 5 years of initiating respiratory rehabilitation.

Obese-related asthma is considered one of the more severe asthma phenotypes.

Data shows certain personality traits are linked to a COPD patient's likelihood of active or sedentary behaviors.

The added indication makes the GSK single inhaler triple therapy the first of its kind approved for both asthma and COPD in the US.

The chief of thoracic surgery and surgical director of the Northwestern Medicine Lung Transplant Program discusses his unprecedented procedure during the pandemic.

New ERS findings show patients hospitalized for COVID-19 bettered from timelier, personalized rehabilitation plans.

The risk of cardiovascular hospitalizations was associated with increasing PM10 at lag 0.

In a poster presented at ERS, researchers find the complement and coagulation cascades pathway was up-regulated in response to airway presence of Moraxella genera that might suggest an activation of systemic innate immunity in response to Moraxella.

COVID-19 positive patients with COPD demonstrated a greater risk for hospitalization, ICU admission, and need for invasive mechanical ventilation compared with non-COPD patients.

Data suggests treatment with the palliative opioid does not affect PCO2 levels, suggesting it is safe in patients with moderate to severe COPD.

Tiotropium plus olodaterol is more effective for patients with COPD compared with LABA plus inhaled corticosteroids.

A new case study  assesses biopsy and autopsy tissues to characterize pathological patterns in suspected EVALI cases .

New findings suggest differing chronic lung diseases are associated with varying risk factors among COVID-19 patients.

The approval are based on a pair of recent phase 3 trials showing the safety and efficacy of budesonide/glycopyrrolate/formoterol fumarate.

Genomics, in combination with patient demographic risks, could help better inform clinicians of persons at risk for worsened chronic pulmonary burden.

Where do investigators go next with the 8000-plus COPD patient research?

In an era of triple therapy combinations, what might a tailored approach look like?

New findings from the 8000-plus patient ETHOS trial shows triple inhaler therapy siginificantly betters patient mortality and symptoms over 52 weeks versus dual therapy.

New findings from ATS show the residual effects of vaping-associated lung distress.

A discussion with a study author on promising new findings for the combination inhaler therapy.

Little is understood about the systemic markers of worsening COPD. Investigators have observed at least 3 novel pathways.

A new assessment shows risk reduction is even more significant among COPD patients who have smoked.

An assessment of FF/UMEC/VI in a single inhaler show its benefit in respiratory function among COPD patients at 24 weeks.

A new study shows consistent confidence and anxiety of self-care with the injectable biologic in patients with asthma.